CureVac, GSK load into starting block in omicron booster race Bayer parts ways with Exscientia, leaving one target in AI drug hunter's hands China's Jemincare nabs $650M biobucks pact with Roche's Genentech for prostate cancer hopeful Astellas' menopause therapy accepted for FDA review 5 months after late-phase study mars record Curis gets FDA green light to restart lymphoma trial, though partial hold on leukemia study stays in place UPDATE: Bluebird bio's $2.8M gene therapy Zynteglo wins FDA backing. Will its US launch take flight? Alzheimer's-linked gene could be key to stymying glaucoma Canadian biotech Lobe Sciences taps Australian CRO iNGENū for psychedelic drug trial CDC plans overhaul to public health efforts in response to monkeypox, COVID-19 criticism As vaccine makers gear up for a busy season, Seqirus exec says influenza is poised for a return Chinese CRO listed on Shenzhen exchange, raises $170M Amid overwhelming opioid litigation, Endo files for bankruptcy and inks $450M settlement Featured Story | By Annalee Armstrong With competitors laps ahead on the track, CureVac and GSK are loading into the starting block for the COVID-19 booster race. The companies announced Thursday morning that a phase 1 trial for their mRNA booster vaccine targeting the omicron variant is getting underway. read more |
| |
|---|
|
Top Stories By Annalee Armstrong Bayer and Exscientia are parting ways on an artificial intelligence collaboration that saw the pair work together to find cardiovascular and oncology targets. Exscientia revealed the end of the collaboration in a second-quarter earnings report issued after-market Wednesday. The U.K.-based AI company will retain the option to develop one of the two targets that were being worked on. read more By Ben Adams After penning a deal with Orion back in May, Jemincare is back at the licensing deal table, inking a development and sales deal with Roche’s Genentech unit that is on the lookout for a new prostate cancer drug after the recent flop of its phase 3 asset ipatasertib. read more By Annalee Armstrong Astellas’ menopause treatment received the FDA’s blessing to be considered for approval five months after the therapy hit a speed bump in a phase 3 trial conducted in Asia. read more By Gabrielle Masson The FDA has green lit Curis' phase 1/2 lymphoma trial, lifting a partial clinical hold on the study assessing emavusertib. Yet, a partial hold remains for the biotech’s leukemia trial evaluating the same drug. read more By Fraiser Kansteiner Ahead of a much awaited FDA decision deadline Friday, the agency endorsed bluebird bio's gene therapy Zynteglo. It'll carry a $2.8 million price tag and is the first gene therapy for this rare disease. read more By Max Bayer New research from scientists at Mass General Brigham suggests that a gene linked with Alzheimer's disease could be critical to glaucoma progression. read more By Ben Adams Lobe Sciences is hiring the Australia-based CRO iNGENū to carry out at least three trials for the Canadian biotech’s psychedelic drug candidates. read more By Robert King CDC announced an overhaul to agency operations to better respond to public health emergencies, including reexamining the communications efforts and eliminating conflicting guidance. read more By Zoey Becker Flu may have slipped the public's mind over the past two years as COVID-19 took center stage, but Seqirus didn't forget. The influenza vaccine specialist is gearing up to supply more than 50 million doses to the U.S. read more By Joseph Keenan Chinese CRO R&G Pharmastudies was recently listed on the ChiNext of the Shenzhen Stock Exchange, raising 1.18 billion yuan ($170 million). read more By Angus Liu Endo has decided to file for bankruptcy in the face of opioid lawsuits to focus on its transformation. Further, the company reached a broad settlement to resolve allegations that it falsely marketed its opioid painkillers. read more | | New Product Planning Summit September 19-20, 2022 | Boston, MA Join us for the ONLY conference for defining how the new product planning role and related functions make informed, value-based, data-driven decisions about products in the pipeline. Register now! |
|---|
Resources Sponsored by: Catalent Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Bio-Techne Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella. Sponsored by: Thermo Fisher Scientific Set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Speid & Associates, Inc. The total immersion, transformative training will take place at the Harvard Club in Boston. VIRTUAL in real time is also available. Contingencies for COVID19 will apply. Register NOW for a large early bird discount www.drugstomarket.com/drugbootcamp. Sponsored by: Triangle Insights Group, LLC The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services. Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. | 